OTCPicks.com Stocks to Watch for Tuesday, February 21st

OTCPicks Publisher Newsletter

OTCPicks.com Stocks to Watch for Tuesday, February 21st GRNE, ECDC, SAVW, MCLN, CHDO, CTIC Our Stocks to Watch tomorrow include Green Endeavors Inc. (OTCBB: GRNE), East Coast Diversified Corp. (OTCBB: ECDC), SavWatt USA Inc. (OTCBB: SAVW), MedClean Technologies Inc. (OTCBB: MCLN), CHDT Corp. (OTCBB: CHDO) and Cell Therapeutics Inc. (NASDAQ: CTIC). Visit http://otcpicknews.com/emailmarketer/link.phpM940&N21&L1&F=T to register for our Stocks to Watch Newsletter and Email Stock Watch Alerts.GREEN ENDEAVORS LIMITED (OTC: GRNE) “Up 150.00% on Friday”Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N21&L84&F=T Green Endeavors, Inc., headquartered in Salt Lake City, Utah, is a holding company with operations in health & beauty. GRNE owns a majority interest in several Aveda™ based businesses. GRNE News:February 16 – GRNE Signs Letter of Intent for New Aveda™ Retail CenterGreen Endeavors, Inc. (OTCBB: GRNE), a majority owned subsidiary of Nexia Holdings, Inc. (OTC: NXHD), announced that its newly formed subsidiary, Landis Experience Center, LLC (LEC), has signed a letter of intent to lease space at Salt Lake City`s City Creek Development, a Taubman property.LEC intends to operate an Aveda™ Experience Center which is a retail shop that sells the full line of Aveda™ products. Aveda™ Experience Centers in the past were owned and operated by Aveda™ directly. Within the last year Aveda™ has allowed a few select salon operators to open and operate Experience Centers. City Creek Mall is a new development in the heart of downtown Salt Lake City, which is within 1.5 miles of GRNE`s Marmalade Landis Lifestyle Salon and 3.5 miles from our flagship Landis Lifestyle Salon in Liberty Heights.The mall developer expects that over 7 million people will visit the center every year. The center is adjacent to the LDS Church`s Temple Square (a major tourist destination), the Salt Lake Convention Center, numerous high rise residential condominiums and public transit services. The mall development and retooling of downtown Salt Lake City is believed to have cost in excess of $1B. It will be the premier shopping center in the state of Utah.GRNE`s CEO, Richard Surber stated, “I have many strategic reasons for opening an Aveda™ LEC. Some of those reasons include: using the center as a means to refer business to our existing Landis Lifestyle Salons, further branding Aveda™ in the Salt Lake market, obtaining Aveda™ corporate training to enhance our retail sales system wide, and further improving our relationship with Aveda™.”EAST COAST DIVERSIFIED CORPORATION (OTCBB: ECDC) “Up 81.58% on Friday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N21&L12&F=T East Coast Diversified Corp. operates through its subsidiary, EarthSearch Communications, Inc. East Coast Diversified Corp. offers a portfolio of GPS devices, RFID interrogators, integrated GPS/RFID technologies and Tag designs. The company was founded in 2010 and is based in Atlanta, Georgia..

ECDC News:February 14 – Rogue Paper`s TV Tune-In App Approaches 800,000 UsersEast Coast Diversified Corporation (OTCBB: ECDC) announced that its subsidiary, Rogue Paper, Inc, and their TV Tune-In platform has experienced nearly 800,000 viewers for their second screen TV applications.Rogue Paper`s TV Tune-In platform allows users a second screen experience for a number of popular TV programs, sporting events and channels, to interact and comment with each other during live broadcasts. Since inception and launch, TV Tune-In has developed a number of apps based off the TV Tune-In platform, and as of now has experienced nearly 800,000 users running the mobile and web-based applications.”Creating and fostering a broad base of viewers on the second screen is a great way for broadcasters to enhance advertising revenues,” Stephanie Boyle, the CEO of Rogue Paper commented. “As we learn more from an expanding user base, we look forward to adding new ways for broadcasters to capitalize on their second screen audiences such as synchronized TV ads and deeper interactivity.”TV Tune-In`s social curation engine, a tool for creating a personal collection of messages from the social sphere to an authenticated user, is processing tens of thousands of messages and comments per live event to give users the best of the best content. It works to provide a tailored stream of information so that users don`t get lost in the wealth of data and irrelevant messages.For more information, time schedule and updates visit: www.roguepaper.comABOUT ROGUE PAPERRogue Paper, a subsidiary of ECDC, is a developer of TV Tune-In Application developed by Rogue Paper. TV Tune-In is a real-time, companion viewing and mobile app development platform for media companies to help drive viewership, conversation and interactions for television shows and content. TV Tune-In`s CMS allows media companies to develop branded iPhone and iPad apps for television shows and channels. Powering such category leading applications as MTV`s WatchWith and VH1`s Co-Star iPhone and iPad applications, users can actively comment along with their favorite show (live or time-shifted). The apps aim to attract fans around live viewing of their favorite show, event, or sports team. Users can actively comment, Tweet and Like their favorite show, chat with friends, play trivia games, watch exclusive video content, photos and more. SAVWATT USA INCORPORATED (OTCBB: SAVW) “Up 100.00% on Friday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N21&L92&F=T Fast becoming the market leader in LED lighting, SavWatt focuses on developing innovative, energy-efficient and cost-effective LED lighting solutions. By delivering value added, application-specific LED lighting systems, we can significantly reduce energy costs and minimize our carbon footprint world-wide. SavWatt is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb. SavWatt`s product families include LED fixtures, bulbs, street lights, and parking lights. SAVW News:February 6 – SavWatt Adds Solar to Its Product Line”SavWatt Depot” to Open in AprilSavWatt USA, Inc. (OTCBB: SAVW), pioneers in LED lighting and the Green Revolution, released a business update summarizing some of the company`s initiatives:Revenue Forecast: 1st quarter 2012 will end our development stage classification and our revenues will begin in 2nd quarter 2012. We have several substantial projects due to close this quarter and we are on target to exceed $10 million in revenues for 2012. California operations will begin in the second quarter of 2012. Due to the nature of the market SavWatt will enter the market creating “SavWatt Depot,” a one-stop shop for contractors and homeowners to pick up energy-efficient home products including LED lights, solar panels, solar water heaters, solar pool heaters, battery storage and other energy efficient products. A 12,000 square foot facility in San Marcos, California is currently being renovated for this launch. The facility will also serve as the company`s west coast offices. Based on this new addition SavWatt`s sales forecast for 2012 is $15 million.New personnel at SavWatt: Julio Ferreira has joined the SavWatt team to identify opportunities in Brazil. Brazil is one of the leading green initiatives countries, and provides SavWatt with huge sales potentials, especially with a focus on the upcoming World Cup Games in 2014. Jim Rivette will be heading our International Division and has booked several meetings for his upcoming trip to Western Africa next month. Sheldon Bender has joined the company as full time adviser to the CEO to explore opportunities in partnering with the State of New of York, BYD.com, a major Chinese supplier of LED Lights, Solar Panels, Storage Batteries and Electric Cars and others.Our Eco-poles have been installed in strategic locations for testing and continued to be installed and upgraded. These tests provide valuable information for deployment of thousands of units worldwide in the upcoming years. A Carbon Credit application will be finalized this quarter with the assumption that a forward sale can be made providing valuable subsidies for their deployment. download our Eco-pole brochure:

http://otcpicknews.com/emailmarketer/link.phpM940&N21&L63&F=T. In addition, our new Sun-poles featuring Solar and Lithium Ion batteries enable simple installation of street lights to be deployed without connectivity to the electric grid. Solar panels` updated technology and pricing, coupled with Federal and State incentives, still make it a commodity that SavWatt will be capitalizing on. Solar panels will be added shortly to our web site.In May 2012, SavWatt will participate in the premier annual US Lightfair exhibition, May 9-11 in Las Vegas. www.lightfair.com. The exhibition has been sold out and it is anticipated 75% of this year`s showing will be LED lights. The fair is expected to attract over 20,000 design, architectural, engineering and industry professionals from around the world.Ike H. Sutton, SavWatt`s CEO, commented, “The DTC Chill, which has made shares of our stock harder and more expensive to trade, has definitely taken a toll on our valuation. Shareholders interested in purchasing shares can contact our office to obtain Broker information that will handle the transaction at minimal fees. A long term solution is being explored as the chill has affected over 500 companies is an obstacle that needs to be dealt with.” MEDCLEAN TECHNOLOGIES INCORPORATED (OTCBB: MCLN) “Up 25.00% on Friday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N21&L74&F=T MedClean Technologies Inc., formerly Aduromed Industries Inc., provides solutions for managing medical waste onsite, including designing, selling, installing and servicing on site (in-situ) turnkey systems to treat regulated medical waste. The Company provides these systems to hospitals and other medical facilities as efficient, safe, cost effective and legally compliant solutions to incineration, off site hauling of untreated waste and other alternative treatment technologies and methodologies. MCLN`s principal products are the MedClean series systems. Also effective January 2, 2009, the Company merged its former wholly owned subsidiary, Aduromed Corporation (Aduromed), with and into the Company. MCLN News:No recent items.CHDT CORPORATION (OTCBB: CHDO) “Up 27.45% on Friday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N21&L&F=T CHDT Corp. is a public holding company that engages, through its wholly owned subsidiaries, in the development, manufacturing, logistics, and distribution of consumer products to retailers and wholesalers throughout North America. CHDO News:February 6 – Capstone Industries Announces Plans to Debut New and Innovative Power Failure Lighting Products at the 2012 International Home + Housewares ShowCHDT Corporation’s subsidiary to introduce decorative power failure lights, always-powered flashlights & nightlights designed to complement any space with unique styleCHDT Corporation (OTCBB: CHDO) (“Company”), a leader in the design and manufacture of specialty power failure lights and innovator of consumer products for the North American and Latin American retail markets, announced today that its wholly-owned subsidiary, Capstone Industries, Inc., will be debuting an expanded line of power failure lights emphasizing the Company’s forward approach to design at the International Home + Housewares Show (IHHS) being held at McCormick Place in Chicago, IL from March 10 through March 13, 2012.Reid Goldstein, President of Capstone Industries, commented, “We expect great reception again this year at the IHHS from our introduction of new product lines which underscore our innovation and creativity — making everyday lighting products which offer designer-appeal and multifunction capabilities that also provide reliable lighting whenever there is a power failure. The significant number of natural and man-made occurrences resulting in loss of electricity throughout the United States has driven an unprecedented demand for our power failure lights. We rapidly responded to this growing need by developing a broader power failure solutions line that will now include decorative power failure lights, flashlights and nightlights.”Capstone received several awards and nods from the prestigious 2011 Housewares Design Awards which are considered “The Oscars of Home Design”..

Capstone was a finalist in Best in Lighting Home Decor and the Outdoor Lighting categories with its new Pathway Lights Multi-Pose Britebook book light and their eBook-Lite. The Company received product placement in the Shows` Go Green booth for its Light Ringers solar 12 LED lamp while its Eco-i-Lite was featured in the Designed Defined booth featuring the previous year’s winners for Product Design.Capstone Industries, Inc. will be located in booth N8457 in the Clean & Contain Expo in the North Building, directly across from the buyer`s lounge and New Product Showcase.CELL THERAPEUTICS INCORPORATED (NASDAQ: CTIC) “Up 21.62% on Friday” Detailed Quote:

http://otcpicknews.com/emailmarketer/link.phpM940&N21&L61&F=T Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, visit www.celltherapeutics.com. CTIC News:February 17 – European Medicines Agency`s Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri™Potentially the First Drug to be Approved as Monotherapy for the Treatment of Adult Patients with Multiple Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas (NHL)Cell Therapeutics, Inc. (NASDAQ: CTIC) (“CTI”) announced that Pixuvri™ (pixantrone dimaleate) has been granted a positive opinion for conditional approval from the European Medicines Agency`s (“EMA”) Committee for Medicinal Products for Human Use (“CHMP“). Based on the CHMP`s recommendation, CTI expects that a conditional marketing authorization for Pixuvri should be granted by the European Commission within the next few months. CHMP recommended Pixuvri for conditional approval as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (“NHL”).If the CHMP`s recommendation is formally adopted by the European Commission, Pixuvri would be approved for marketing in the 27 countries that are members of the E.U., as well as the European Economic Area. The decision by the European Commission is typically issued approximately two to three months after the CHMP opinion and generally follows the recommendation from the CHMP. If the opinion is confirmed by the European Commission, Pixuvri would be the first drug approved for patients in this setting. “We are very pleased with the CHMP`s positive recommendation recognizing the clinical benefit of Pixuvri in addressing a significant unmet medical need for patients with multiple relapsed or refractory aggressive B-cell NHL, and we believe that Pixuvri will add an important treatment option for physicians and provide a meaningful impact on patients,” stated James A.

Bianco, CEO of CTI.”There are currently no proven effective therapies for these advanced NHL patients. Our goal for this late stage patient population is to control disease progression and symptoms as a cure is no longer an option. We are encouraged by the PFS noted in the PIX301 study and the opportunity this agent provides in treating this difficult to treat group of patients,” said Bertrand Coiffier, M.D., Ph.D., Professor of Hematology at the Department of Hematology, Hospices Civils de Lyon and the University Lyon 1 in Lyon, France. Similar to accelerated approval regulations in the United States, conditional marketing authorizations are granted to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit. A conditional marketing authorization is renewable annually. Under the provisions of the conditional marketing authorization for Pixuvri, CTI will be required to complete a post-marketing study aimed at confirming the clinical benefit previously observed.The CHMP has accepted PIX306, CTI`s ongoing randomized controlled phase 3 clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in 2nd line patients with aggressive B­cell NHL who failed front-line CHOP-R and who are not eligible for autologous stem cell transplant (“ASCT“) or as 3rd or 4th line therapy in aggressive B-cell NHL. As a condition of approval, CTI has agreed to have available the PIX306 clinical trial results by June 2015.ABOUT NON-HODGKIN LYMPHOMANHL is caused by the abnormal proliferation of lymphocytes, cells key to the functioning of the immune system. It usually originates in lymph nodes and spreads through the lymphatic system. NHL can be broadly classified into two main forms—aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly. The World Health Organization`s International Agency for Research on Cancer`s 2008 GLOBOCAN database most recent estimates state that in European Union approximately 74,162 people will be diagnosed with NHL and 31,371 are estimated to die from NHL every year.There are many subtypes of NHL, but aggressive NHL is one of the more common types of NHL and accounts for about 60% of cases. Initial therapy for aggressive NHL with anthracycline-based combination therapy cures up to 60% of patients. Of the remaining patients, approximately half will respond to second-line treatment, but few are cured and there is no effective therapy for patients relapsing after or refractory to second-line treatment.ABOUT PIXUVRI (PIXANTRONE)Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines — rather than intercalation with DNA — pixantrone alkylates DNA — forming stable DNA adducts with particular specificity for CpG-rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone in an effort to prevent the binding of iron and perpetuation of superoxide production — both of which are the putative mechanism for anthracycline induced acute cardiotoxicity..

These novel pharmacologic differences may allow re-introduction of anthracycline-like potency in the treatment of relapsed/refractory B-cell NHL without unacceptable rates of cardiotoxicity.OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com.This email address is being protected from spam bots, you need Javascript enabled to view it..DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies. The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them. Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research. Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing. Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company`s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company`s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company`s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://otcpicknews.com/emailmarketer/link.phpM940&N21&L=7&F=T and FINRA at http://otcpicknews.com/emailmarketer/link.phpM940&N21&L=8&F=T. Disclosure: OTCPicks.com and affiliates have been not been compensated by any of the companies covered in this release.

Related posts:

1. OTCPicks.com Daily Market Movers Digest Midday Report for Friday, February 17th
2. OTCPicks.com Daily Market Movers Digest Midday Report for Wednesday, February 15th
3. OTCPicks.com Stocks to Watch for Thursday, February 16th
4. OTCPicks.com Stocks to Watch for Tuesday, October 25th
5. OTCPicks.com Stocks to Watch for Friday, February 17th